Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Share-based Compensation (2016 - 2025)

Fennec Pharmaceuticals' Share-based Compensation history spans 15 years, with the latest figure at $2.5 million for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation rose 124.38% year-over-year to $2.5 million, compared with a TTM value of $7.0 million through Dec 2025, up 38.96%, and an annual FY2025 reading of $7.0 million, up 38.96% over the prior year.
  • Share-based Compensation for Q4 2025 was $2.5 million at Fennec Pharmaceuticals, up from $2.2 million in the prior quarter.
  • The five-year high for Share-based Compensation was $2.5 million in Q2 2023, with the low at $30000.0 in Q4 2022.
  • Average Share-based Compensation over 5 years is $1.2 million, with a median of $1.1 million recorded in 2023.
  • Year-over-year, Share-based Compensation skyrocketed 6214.29% in 2021 and then plummeted 94.21% in 2022.
  • Tracing FENC's Share-based Compensation over 5 years: stood at $917000.0 in 2021, then tumbled by 96.73% to $30000.0 in 2022, then skyrocketed by 2756.67% to $857000.0 in 2023, then skyrocketed by 31.16% to $1.1 million in 2024, then soared by 124.38% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for FENC's Share-based Compensation are $2.5 million (Q4 2025), $2.2 million (Q3 2025), and $1.5 million (Q2 2025).